Amgen reported strong Q1 performance with revenue up 5% and EPS up 22%, maintaining full-year guidance and demonstrating robust pipeline advancements, particularly with TVEC's positive results. Management's optimistic outlook and strategic initiatives are likely to bolster investor confidence in the short term.

[1]